Lexeo Therapeutics
Revolutionizes human health therapeutics by applying the science of gene therapy to treat and cure some of the world’s most devastating genetic and acquired diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | $80.0m | Private Placement VC | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 220 % | (61 %) | - | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (3054 %) | (8875 %) | - | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (3055 %) | (9064 %) | - | - | - | - | (317 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2723 % | 7517 % | - | - | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
LEXEO Therapeutics, founded in 2018, is a biotechnology company based in New York that specializes in gene therapy. The company focuses on developing treatments for both common and rare diseases, particularly in the areas of cardiac and neurological conditions. Leveraging a strong research foundation from Weill Cornell Department of Genetic Medicine, LEXEO aims to address unmet medical needs through pioneering genetic medicine. The company serves patients who suffer from genetic disorders and collaborates with clinicians and researchers to bring advanced therapies to market. LEXEO operates in the biotech sector, targeting healthcare providers, medical institutions, and patients as its primary clients. The business model is centered around research and development, clinical trials, and eventual commercialization of gene therapies. Revenue is generated through partnerships, grants, and future sales of approved therapies.
Keywords: gene therapy, biotechnology, cardiac diseases, neurological diseases, genetic research, clinical trials, rare diseases, healthcare, biotech sector, medical innovation.
Tech stack
Investments by Lexeo Therapeutics
Edit